| Members |
targetComponentId |
| parodontit samtidigt med Downs syndrom |
Periodontitis exacerbated by Down syndrome |
| parodontit samtidigt med Ehlers-Danlos syndrom typ 4 |
Periodontitis due to Ehlers-Danlos syndrome type 4 (disorder) |
| parodontit samtidig med förvärvad neutropeni |
Periodontitis exacerbated by acquired neutropenia |
| parodontit samtidigt med cyklisk neutropeni |
Periodontitis exacerbated by cyclical neutropenia (disorder) |
| parodontit samtidigt med familjär neutropeni |
Periodontitis exacerbated by familial neutropenia |
| parodontit samtidig med glykogeninlagringssjukdom |
Periodontitis exacerbated by glycogen storage disease |
| parodontit samtidigt med hypofosfatasi |
Periodontitis exacerbated by hypophosphatasia (disorder) |
| parodontit samtidig med infantil genetisk agranulocytos |
Periodontitis due to infantile genetic agranulocytosis (disorder) |
| parodontit samtidigt med leukocytadherensdefekt |
Periodontitis due to leukocyte adhesion deficiency |
| Periostitis of other specified site, NEC |
Periostitis |
| perifert T-cellslymfom |
Peripheral T-cell lymphoma |
| Peripheral T-cell lymphoma, pleomorphic medium and large cell |
Peripheral T-cell lymphoma |
| Peripheral T-cell lymphoma, pleomorphic small cell |
Peripheral T-cell lymphoma |
| cytostatikautlöst perifer neuropati |
Peripheral neuropathy due to and following antineoplastic therapy (disorder) |
| åtgärder för tamponad av peritoneum |
Insertion of pack into peritoneal cavity (procedure) |
| undersökning av peritoneal venös shunts öppenhet för Leveen-shunt |
Peritoneovenous shunt patency test |
| Personal history of primary malignant neoplasm of skin |
History of primary malignant neoplasm of skin (situation) |
| Personality finding |
Character trait finding |
| Pesticide product overdose |
Pesticide poisoning |
| Petit mal |
Absence seizure |
| Petroleum poisoning |
Toxic effect of petroleum product |
| Phalanx of second finger |
Structure of phalanx of index finger |
| farmaceutiskt smörjmedel |
Medicinal product acting as lubricant (product) |
| faryngorafi vid kluven gom |
Repair of cleft palate |
| Pharynx excision |
Pharyngectomy |
| adenovirus 1 hos fasan |
Turkey adenovirus 3 (organism) |
| Phendimetrazine tartrate 105mg capsule |
Phendimetrazine only product in oral dose form |
| fendimetrazintartrat 105 mg, kapsel med modifierad frisättning |
Phendimetrazine only product in oral dose form |
| fendimetrazintartrat 105 mg, depåkapsel |
Phendimetrazine only product in oral dose form |
| feniramin 0,0315 %/nafazolin 0,02675 %, lösning för oftalmiskt bruk |
Naphazoline hydrochloride 270 microgram/mL and pheniramine maleate 3.15 mg/mL eye solution |
| pentobarbital 20 mg/5 ml, elixir |
Product containing precisely phenobarbital 4 milligram/1 milliliter conventional release oral solution (clinical drug) |
| överdos av fentiazin |
Phenothiazine and/or phenothiazine derivative overdose |
| fenoxibensaminhydroklorid 50 mg/ml, injektionskoncentrat, ampull 2 ml |
Product containing precisely phenoxybenzamine hydrochloride 50 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| fenoximetylpenicillin 0,3 %, ögondroppar |
Phenoxymethylpenicillin potassium 3 mg/mL eye solution |
| Phenylacetate--CoA ligase |
Phenylacetate--CoA ligase |
| antipsykotiskt medel innehållande fenylbutylpiperadinderivat |
Phenylbutylpiperadine derivative |
| fenylefrin 0,125 % lösning, näsdroppar |
Product containing precisely phenylephrine hydrochloride 1.25 milligram/1 milliliter conventional release nasal solution (clinical drug) |
| fenylefrin 0,25 %, lösning för nasalt bruk |
Product containing precisely phenylephrine hydrochloride 2.5 milligram/1 milliliter conventional release nasal solution (clinical drug) |
| fenylefrin 0,25 %, lösning för oralt bruk, droppar |
Phenylephrine 2.5 mg/mL oral solution |
| fenylefrin 0,5 %, lösning för nasalt bruk |
Product containing precisely phenylephrine hydrochloride 5 milligram/1 milliliter conventional release nasal solution (clinical drug) |
| fenylefrin 1 %, lösning för nasalt bruk |
Phenylephrine hydrochloride 10 mg/mL nasal solution |
| fenylefrin 5 mg/5 ml + prometazin 6,25 mg/5 ml + kodein 10 mg/5 ml, oral sirap |
Codeine phosphate 2 mg/mL and phenylephrine hydrochloride 1 mg/mL and promethazine hydrochloride 1.25 mg/mL oral solution |
| fenylefrinhydroklorid 10 %, ögondroppar |
Phenylephrine hydrochloride 100 mg/mL eye solution |
| fenylefrinhydroklorid 10 %, ögondroppar för engångsbruk |
Phenylephrine hydrochloride 100 mg/mL eye solution |
| fenylefrinhydroklorid 2,5 %, ögondroppar |
Phenylephrine hydrochloride 25 mg/mL eye solution |
| fenylefrinhydroklorid 2,5 %, ögondroppar för engångsbruk |
Phenylephrine hydrochloride 25 mg/mL eye solution |
| fenylefrinhydroklorid 2,5 %, lösning |
Product containing only phenylephrine (medicinal product) |
| antidepressivt läkemedel innehållande fenylpiperazin |
Phenylpiperazine derivative (substance) |
| biverkning av fenylpropanolaminhydroklorid |
Adverse reaction to phenylpropanolamine |
| fenylpropanolaminhydrokloridallergi |
Allergy to phenylpropanolamine (finding) |
| natriumfenytoin 30 mg, kapsel med modifierad frisättning |
Phenytoin only product in oral dose form |
| fenytoinnatrium 30 mg, depåkapsel |
Phenytoin only product in oral dose form |
| Phialophora richardsiae |
Pleurostomophora richardsiae (organism) |
| Phocanema decipiens |
Pseudoterranova decipiens |
| folkolin |
Pholcodine (substance) |
| Phosphocol (^32^P) 15 millicurie, injektionsvätska, suspension, flaska 10 ml |
Chromic phosphate (32-P) only product in parenteral dose form |
| fosfolipasspecifikt extrakt |
Product containing phospholipase (medicinal product) |
| fosfolipid 35 mg + protein 0,65 mg, suspension |
Product containing only calfactant (medicinal product) |
| Phosphoric diester hydrolase |
Phosphoric diester hydrolase |
| Phosphoric monoester hydrolase |
Substance with phosphoric monoester hydrolase mechanism of action (substance) |
| ^32^P, diagnostiskt |
Product containing phosphorus-32 (medicinal product) |
| Phosphorus-oxygen lyase |
Phosphorus-oxygen lyase |
| Phosphotransferase |
Kinase |
| Photoptarmosis |
Photoptarmosis |
| Photorhabdus luminescens, underart thracensis |
Photorhabdus temperata subspecies thracensis (organism) |
| Photosensitising drugs |
Drug or medicament (substance) |
| ftalsyraanhydridspecifikt extrakt |
Phthalic anhydride |
| Phthisis bulbi |
Phthisis bulbi |
| fylumet Thermomicrobia |
Class Thermomicrobia (organism) |
| Phylum acanthocephala |
Phylum Acanthocephala (organism) |
| Phylum microspora |
Phylum Microsporidia (organism) |
| Physical examination - action |
Examination - action |
| Physical medicine iontophoresis |
Iontophoresis procedure |
| fysikalisk medicinsk behandling |
Physical medicine service (qualifier value) |
| Physical science technician |
Physics technician |
| fysostigmin 0,25 %, ögondroppar |
Product containing precisely physostigmine salicylate 2.5 milligram/1 milliliter conventional release eye solution (clinical drug) |
| fysostigmin 0,5 %, ögondroppar |
Product containing precisely physostigmine salicylate 5 milligram/1 milliliter conventional release eye solution (clinical drug) |
| fysostigmin 0,25 % + pilokarpin 2 %, ögondroppar |
Physostigmine salicylate 2.5 mg/mL and pilocarpine hydrochloride 20 mg/mL eye solution |
| fysostigmin 0,25 % + pilokarpin 4 %, ögondroppar |
Product containing precisely physostigmine salicylate 2.5 milligram/1 milliliter and pilocarpine hydrochloride 40 milligram/1 milliliter conventional release eye solution (clinical drug) |
| fysostigmin 0,5 % + pilokarpin 4 %, ögondroppar |
Product containing precisely physostigmine salicylate 5 milligram/1 milliliter and pilocarpine hydrochloride 40 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Pichia ohmeri |
Kodamaea ohmeri (organism) |
| Pick's cell |
Niemann-Pick cell |
| Picornavirus |
Family Picornaviridae (organism) |
| pigmenterat nevus |
Pigmented nevus |
| pigmenterad hudlesion av misstänkt malign typ |
Suspected malignant pigmented skin lesion (situation) |
| pilokarpinhydroklorid 10 %, ögondroppar |
Product containing precisely pilocarpine hydrochloride 100 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Pilocarpine hydrochloride 5.0mg tablet |
Product containing precisely pilocarpine hydrochloride 5 milligram/1 each conventional release oral tablet (clinical drug) |
| pilokarpinnitrat 1 %, ögondroppar |
Product containing only pilocarpine in ocular dose form (medicinal product form) |
| pilokarpinnitrat 1 %, ögondroppar för engångsbruk |
Product containing only pilocarpine in ocular dose form (medicinal product form) |
| pilokarpinnitrat 2 %, ögondroppar |
Product containing only pilocarpine in ocular dose form (medicinal product form) |
| pilokarpinnitrat 2 %, ögondroppar för engångsbruk |
Product containing only pilocarpine in ocular dose form (medicinal product form) |
| pilokarpinnitrat 4 %, ögondroppar |
Product containing only pilocarpine in ocular dose form (medicinal product form) |
| pilokarpinnitrat 4 %, ögondroppar för engångsbruk |
Product containing only pilocarpine in ocular dose form (medicinal product form) |
| Pilocarpine nitrate 4% single-use eye drops |
Product containing only pilocarpine in ocular dose form (medicinal product form) |
| Pilocytic astrocytoma |
Pilocytic astrocytoma |
| Pilonidal cyst with no abscess |
Pilonidal cyst |
| pioglitazon 15 mg + metformin 1 g, tablett med modifierad frisättning |
Metformin and pioglitazone only product in oral dose form |
| pioglitazon 15 mg + metformin 1 g, depåtablett |
Metformin and pioglitazone only product in oral dose form |
| pioglitazon 30 mg + metformin 1 g, tablett med modifierad frisättning |
Metformin and pioglitazone only product in oral dose form |
| pioglitazon 30 mg + metformin 1 g, depåtablett |
Metformin and pioglitazone only product in oral dose form |
| piperacillin 1 g, pulver till injektionsvätska, flaska |
Product containing precisely piperacillin anhydrous (as piperacillin sodium) 1 gram/1 vial powder for conventional release solution for injection (clinical drug) |
FHIR